Christopher Ray Aker Regulus Therapeutics Inc. (RGLS) insider trading activity

RGLS Quotes by TradingView

Christopher Ray Aker is Sr. VP & General Counsel of Regulus Therapeutics Inc.. Currently has a direct ownership of 10,056 shares of RGLS, which is worth approximately $14,782. The most recent transaction as insider was on Jan 18, 2024, when has been sold 5,468 shares (Common Stock) at a price of $1.19 per share, resulting in proceeds of $6,506. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 10.1K
0% 3M change
75.92% 12M change
Total Value Held $14,782

Christopher Ray Aker Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 18 2024
SELL
Open market or private sale
$6,506 $1.19 p/Share
5,468 Reduced 35.22%
10,056 Common Stock
Jan 12 2024
BUY
Grant, award, or other acquisition
-
11,250 Added 42.02%
15,524 Common Stock
May 17 2021
SELL
Open market or private sale
$765 $0.89 p/Share
860 Reduced 2.02%
41,754 Common Stock
Feb 16 2021
SELL
Open market or private sale
$1,424 $1.72 p/Share
828 Reduced 1.91%
42,614 Common Stock
Nov 16 2020
SELL
Open market or private sale
$456 $0.52 p/Share
876 Reduced 3.29%
25,762 Common Stock
CRA

Christopher Ray Aker

Sr. VP & General Counsel
San Diego, CA

Track Institutional and Insider Activities on RGLS

Follow Regulus Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGLS shares.

Notify only if

Insider Trading

Get notified when an Regulus Therapeutics Inc. insider buys or sells RGLS shares.

Notify only if

News

Receive news related to Regulus Therapeutics Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RGLS